{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T04:09:21Z","timestamp":1749010161783,"version":"3.41.0"},"reference-count":38,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100001818","name":"Research to Prevent Blindness","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001818","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["NEI-NIH P30 EYE030413"],"award-info":[{"award-number":["NEI-NIH P30 EYE030413"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000009","name":"Foundation for the National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000009","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Ophthalmology Retina"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.oret.2024.11.014","type":"journal-article","created":{"date-parts":[[2024,11,21]],"date-time":"2024-11-21T02:45:28Z","timestamp":1732157128000},"page":"564-569","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Outcomes and Need for Additional Interventions after Intravitreal Bevacizumab for Retinopathy of Prematurity"],"prefix":"10.1016","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4892-833X","authenticated-orcid":false,"given":"Ally J.","family":"Sun","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2574-6207","authenticated-orcid":false,"given":"Brisa Y.","family":"Garcia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5407-7527","authenticated-orcid":false,"given":"Hank","family":"Patrick","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu-Guang","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5552-371X","authenticated-orcid":false,"given":"Angeline L.","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.oret.2024.11.014_bib1","doi-asserted-by":"crossref","first-page":"240","DOI":"10.3928\/01913913-20210122-02","article-title":"Effects of early treatment of retinopathy of prematurity at a tertiary care hospital in Saudi Arabia: a retrospective study","volume":"58","author":"Danish","year":"2021","journal-title":"J Pediatr Ophthalmol Strabismus"},{"key":"10.1016\/j.oret.2024.11.014_bib2","doi-asserted-by":"crossref","first-page":"2515","DOI":"10.1056\/NEJMra1208129","article-title":"Mechanisms and management of retinopathy of prematurity","volume":"367","author":"Hartnett","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.oret.2024.11.014_bib3","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2018-3061","article-title":"Screening examination of premature infants for retinopathy of prematurity","volume":"142","author":"Fierson","year":"2018","journal-title":"Pediatrics"},{"key":"10.1016\/j.oret.2024.11.014_bib4","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2021-053924","article-title":"Retinopathy of prematurity: a global perspective and recent developments","volume":"150","author":"Sabri","year":"2022","journal-title":"Pediatrics"},{"key":"10.1016\/j.oret.2024.11.014_bib5","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1007\/s10103-011-1021-z","article-title":"Laser treatment for retinopathy of prematurity","volume":"28","author":"Houston","year":"2013","journal-title":"Lasers Med Sci"},{"key":"10.1016\/j.oret.2024.11.014_bib6","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1001\/archopht.121.12.1684","article-title":"Revised indications for the treatment of retinopathy of prematurity: results of the early treatment for retinopathy of prematurity randomized trial","volume":"121","year":"2003","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.oret.2024.11.014_bib7","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1055\/s-0040-1713181","article-title":"Update in the treatment of retinopathy of prematurity","volume":"39","author":"Bancalari","year":"2022","journal-title":"Am J Perinatol"},{"key":"10.1016\/j.oret.2024.11.014_bib8","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0225643","article-title":"Development of refractive error in children treated for retinopathy of prematurity with anti-vascular endothelial growth factor (anti-VEGF) agents: a meta-analysis and systematic review","volume":"14","author":"Tan","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.oret.2024.11.014_bib9","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1001\/jama.2022.10564","article-title":"Effect of intravitreal aflibercept vs laser photocoagulation on treatment success of retinopathy of prematurity: the FIREFLEYE randomized clinical trial","volume":"328","author":"Stahl","year":"2022","journal-title":"JAMA"},{"key":"10.1016\/j.oret.2024.11.014_bib10","doi-asserted-by":"crossref","first-page":"305.e1","DOI":"10.1016\/j.jaapos.2022.08.524","article-title":"Structural and refractive outcomes of intravitreal ranibizumab followed by laser photocoagulation for type 1 retinopathy of prematurity","volume":"26","author":"Hoppe","year":"2022","journal-title":"J AAPOS"},{"key":"10.1016\/j.oret.2024.11.014_bib11","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1056\/NEJMoa1007374","article-title":"Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity","volume":"364","author":"Mintz-Hittner","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.oret.2024.11.014_bib12","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/j.ophtha.2016.12.025","article-title":"Anti-vascular endothelial growth factor therapy for primary treatment of type 1 retinopathy of prematurity: a report by the American Academy of Ophthalmology","volume":"124","author":"VanderVeen","year":"2017","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2024.11.014_bib13","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.ajo.2020.05.025","article-title":"Retinopathy of prematurity: evolving treatment with anti-vascular endothelial growth factor","volume":"218","author":"Hartnett","year":"2020","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.oret.2024.11.014_bib14","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1007\/s10792-021-02188-z","article-title":"Comparison of bevacizumab, ranibizumab and aflibercept in retinopathy of prematurity treatment","volume":"42","author":"S\u00fcren","year":"2022","journal-title":"Int Ophthalmol"},{"key":"10.1016\/j.oret.2024.11.014_bib15","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1016\/j.ophtha.2022.06.042","article-title":"A network meta-analysis of retreatment rates following bevacizumab, ranibizumab, aflibercept, and laser for retinopathy of prematurity","volume":"129","author":"Chang","year":"2022","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2024.11.014_bib16","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.ophtha.2022.11.012","article-title":"Comparison in retreatments between bevacizumab and ranibizumab intravitreal injections for retinopathy of prematurity: a multicenter study","volume":"130","author":"Patel","year":"2023","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2024.11.014_bib17","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1016\/j.ophtha.2014.12.017","article-title":"Outcomes after intravitreal bevacizumab versus laser photocoagulation for retinopathy of prematurity: a 5-year retrospective analysis","volume":"122","author":"Hwang","year":"2015","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2024.11.014_bib18","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1097\/IAE.0000000000002663","article-title":"Rates and risk factors for recurrence of retinopathy of prematurity after laser or intravitreal anti-vascular endothelial growth factor monotherapy","volume":"40","author":"Ling","year":"2020","journal-title":"Retina"},{"key":"10.1016\/j.oret.2024.11.014_bib19","doi-asserted-by":"crossref","first-page":"3302","DOI":"10.1038\/s41433-021-01413-4","article-title":"The results of intravitreal bevacizumab monotherapy for treating aggressive posterior retinopathy of prematurity and Type 1 retinopathy of prematurity","volume":"35","author":"\u00c7\u00f6mez","year":"2021","journal-title":"Eye (Lond)"},{"key":"10.1016\/j.oret.2024.11.014_bib20","doi-asserted-by":"crossref","first-page":"778585","DOI":"10.3389\/fped.2022.778585","article-title":"Aggressive posterior retinopathy of prematurity: long-term outcomes following intravitreal bevacizumab","volume":"10","author":"Naravane","year":"2022","journal-title":"Front Pediatr"},{"key":"10.1016\/j.oret.2024.11.014_bib21","doi-asserted-by":"crossref","first-page":"255","DOI":"10.3928\/23258160-20170301-10","article-title":"Reactivation of retinopathy of prematurity three years after treatment with bevacizumab","volume":"48","author":"Hajrasouliha","year":"2017","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"key":"10.1016\/j.oret.2024.11.014_bib22","doi-asserted-by":"crossref","first-page":"280","DOI":"10.3928\/23258160-20160229-12","article-title":"Very late reactivation of retinopathy of prematurity after monotherapy with intravitreal bevacizumab","volume":"47","author":"Snyder","year":"2016","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"key":"10.1016\/j.oret.2024.11.014_bib23","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1167\/iovs.16-20680","article-title":"Recurrence of retinopathy of prematurity after intravitreal ranibizumab monotherapy: timing and risk factors","volume":"58","author":"Lyu","year":"2017","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.oret.2024.11.014_bib24","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1016\/j.ophtha.2016.04.028","article-title":"Clinical management of recurrent retinopathy of prematurity after intravitreal bevacizumab monotherapy","volume":"123","author":"Mintz-Hittner","year":"2016","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2024.11.014_bib25","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1016\/j.ophtha.2015.05.036","article-title":"Frizzled-4 variations associated with retinopathy and intrauterine growth retardation: a potential marker for prematurity and retinopathy","volume":"122","author":"Dailey","year":"2015","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2024.11.014_bib26","doi-asserted-by":"crossref","first-page":"e417","DOI":"10.1111\/aos.13008","article-title":"Efficacy of intravitreal bevacizumab for zone-II retinopathy of prematurity","volume":"94","author":"Karkhaneh","year":"2016","journal-title":"Acta Ophthalmol"},{"key":"10.1016\/j.oret.2024.11.014_bib27","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1097\/IAE.0000000000001996","article-title":"Fluorescein angiographic evaluation of peripheral retinal vasculature after primary intravitreal ranibizumab for retinopathy of prematurity","volume":"39","author":"Harper","year":"2019","journal-title":"Retina"},{"key":"10.1016\/j.oret.2024.11.014_bib28","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.jaapos.2021.09.004","article-title":"Prevalence of persistent avascular retina in untreated children with a history of retinopathy of prematurity screening","volume":"26","author":"Hanif","year":"2022","journal-title":"J AAPOS"},{"key":"10.1016\/j.oret.2024.11.014_bib29","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1016\/j.ophtha.2022.05.019","article-title":"Low- and very low-dose bevacizumab for retinopathy of prematurity: reactivations, additional treatments, and 12-month outcomes","volume":"129","author":"Freedman","year":"2022","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2024.11.014_bib30","doi-asserted-by":"crossref","first-page":"100281","DOI":"10.1016\/j.xops.2023.100281","article-title":"Persistent vascular anomalies in retinopathy of prematurity children: ultrawide-field fluorescein angiography findings until school age","volume":"3","author":"Ling","year":"2023","journal-title":"Ophthalmol Sci"},{"key":"10.1016\/j.oret.2024.11.014_bib31","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1080\/08164622.2022.2053329","article-title":"Long-term visual outcomes of children screened for retinopathy of prematurity with telemedicine in New Zealand","volume":"106","author":"Simkin","year":"2023","journal-title":"Clin Exp Optom"},{"key":"10.1016\/j.oret.2024.11.014_bib32","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1016\/j.survophthal.2021.02.012","article-title":"Neurodevelopmental outcomes in preterm infants with retinopathy of prematurity","volume":"66","author":"Tan","year":"2021","journal-title":"Surv Ophthalmol"},{"key":"10.1016\/j.oret.2024.11.014_bib33","doi-asserted-by":"crossref","first-page":"220","DOI":"10.3928\/23258160-20200326-03","article-title":"Neurodevelopmental outcomes following intravitreal bevacizumab with laser versus laser photocoagulation alone for retinopathy of prematurity","volume":"51","author":"Ahmed","year":"2020","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"key":"10.1016\/j.oret.2024.11.014_bib34","doi-asserted-by":"crossref","first-page":"e0230678","DOI":"10.1371\/journal.pone.0230678","article-title":"Neurodevelopmental outcomes following intravitreal bevacizumab injection in Japanese preterm infants with type 1 retinopathy of prematurity","volume":"15","author":"Arima","year":"2020","journal-title":"PLoS One"},{"key":"10.1016\/j.oret.2024.11.014_bib35","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1080\/14767058.2021.1888913","article-title":"Bevacizumab and neurodevelopmental outcomes of preterm infants with retinopathy of prematurity: should we still worry?","volume":"35","author":"Celik","year":"2022","journal-title":"J Matern Fetal Neonatal Med"},{"key":"10.1016\/j.oret.2024.11.014_bib36","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1038\/s41372-019-0420-z","article-title":"Neurodevelopmental outcomes in infants treated with intravitreal bevacizumab versus laser","volume":"39","author":"Raghuram","year":"2019","journal-title":"J Perinatol"},{"key":"10.1016\/j.oret.2024.11.014_bib37","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1016\/j.ophtha.2020.11.012","article-title":"Neurodevelopmental outcomes after bevacizumab treatment for retinopathy of prematurity: a meta-analysis","volume":"128","author":"Tsai","year":"2021","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2024.11.014_bib38","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1097\/ANC.0000000000000881","article-title":"Neurodevelopmental outcomes associated with intravitreal bevacizumab injections for retinopathy of prematurity","volume":"22","author":"Webb","year":"2022","journal-title":"Adv Neonatal Care"}],"container-title":["Ophthalmology Retina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468653024005487?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468653024005487?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T07:48:37Z","timestamp":1748936917000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468653024005487"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":38,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["S2468653024005487"],"URL":"https:\/\/doi.org\/10.1016\/j.oret.2024.11.014","relation":{},"ISSN":["2468-6530"],"issn-type":[{"type":"print","value":"2468-6530"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Outcomes and Need for Additional Interventions after Intravitreal Bevacizumab for Retinopathy of Prematurity","name":"articletitle","label":"Article Title"},{"value":"Ophthalmology Retina","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.oret.2024.11.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 by the American Academy of Ophthalmology","name":"copyright","label":"Copyright"}]}}